Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Profitability
This table compares Ultragenyx Pharmaceutical and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ultragenyx Pharmaceutical | -71.78% | N/A | -39.70% |
| Altimmune | N/A | -29.26% | -25.48% |
Valuation & Earnings
This table compares Ultragenyx Pharmaceutical and Altimmune”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ultragenyx Pharmaceutical | $673.00 million | 2.42 | -$575.00 million | ($5.19) | -3.08 |
| Altimmune | $31,000.00 | 9,506.28 | -$88.09 million | ($0.72) | -2.10 |
Altimmune has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Ultragenyx Pharmaceutical and Altimmune, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ultragenyx Pharmaceutical | 1 | 11 | 9 | 1 | 2.45 |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
Ultragenyx Pharmaceutical presently has a consensus target price of $29.79, indicating a potential upside of 86.20%. Altimmune has a consensus target price of $14.33, indicating a potential upside of 846.09%. Given Altimmune’s stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Ultragenyx Pharmaceutical.
Insider & Institutional Ownership
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Summary
Altimmune beats Ultragenyx Pharmaceutical on 8 of the 15 factors compared between the two stocks.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
